Literature DB >> 34651585

Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside.

Erik S Musiek1, Teresa Gomez-Isla2,3, David M Holtzman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34651585      PMCID： PMC8516468          DOI： 10.1172/JCI154889

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   19.456


× No keyword cloud information.
  12 in total

1.  Donanemab in Early Alzheimer's Disease.

Authors:  Mark A Mintun; Albert C Lo; Cynthia Duggan Evans; Alette M Wessels; Paul A Ardayfio; Scott W Andersen; Sergey Shcherbinin; JonDavid Sparks; John R Sims; Miroslaw Brys; Liana G Apostolova; Stephen P Salloway; Daniel M Skovronsky
Journal:  N Engl J Med       Date:  2021-03-13       Impact factor: 91.245

2.  The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Authors:  Jeff Sevigny; Ping Chiao; Thierry Bussière; Paul H Weinreb; Leslie Williams; Marcel Maier; Robert Dunstan; Stephen Salloway; Tianle Chen; Yan Ling; John O'Gorman; Fang Qian; Mahin Arastu; Mingwei Li; Sowmya Chollate; Melanie S Brennan; Omar Quintero-Monzon; Robert H Scannevin; H Moore Arnold; Thomas Engber; Kenneth Rhodes; James Ferrero; Yaming Hang; Alvydas Mikulskis; Jan Grimm; Christoph Hock; Roger M Nitsch; Alfred Sandrock
Journal:  Nature       Date:  2016-09-01       Impact factor: 49.962

Review 3.  Cerebral amyloid angiopathy in the elderly.

Authors:  Anand Viswanathan; Steven M Greenberg
Journal:  Ann Neurol       Date:  2011-12       Impact factor: 10.422

4.  Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.

Authors:  Michael C Donohue; Reisa A Sperling; Ronald Petersen; Chung-Kai Sun; Michael W Weiner; Paul S Aisen
Journal:  JAMA       Date:  2017-06-13       Impact factor: 56.272

5.  Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease.

Authors:  T Gómez-Isla; R Hollister; H West; S Mui; J H Growdon; R C Petersen; J E Parisi; B T Hyman
Journal:  Ann Neurol       Date:  1997-01       Impact factor: 10.422

6.  Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease.

Authors:  P V Arriagada; K Marzloff; B T Hyman
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

7.  Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.

Authors:  Jeffrey Cummings; Paul Aisen; Cynthia Lemere; Alireza Atri; Marwan Sabbagh; Stephen Salloway
Journal:  Alzheimers Res Ther       Date:  2021-05-10       Impact factor: 6.982

Review 8.  NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Authors:  Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling
Journal:  Alzheimers Dement       Date:  2018-04       Impact factor: 21.566

9.  Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials.

Authors:  J Scott Andrews; Urvi Desai; Noam Y Kirson; Miriam L Zichlin; Daniel E Ball; Brandy R Matthews
Journal:  Alzheimers Dement (N Y)       Date:  2019-08-02

10.  A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Authors:  Chad J Swanson; Yong Zhang; Shobha Dhadda; Jinping Wang; June Kaplow; Robert Y K Lai; Lars Lannfelt; Heather Bradley; Martin Rabe; Akihiko Koyama; Larisa Reyderman; Donald A Berry; Scott Berry; Robert Gordon; Lynn D Kramer; Jeffrey L Cummings
Journal:  Alzheimers Res Ther       Date:  2021-04-17       Impact factor: 8.823
View more
  4 in total

Review 1.  New Insights into Neuroinflammation Involved in Pathogenic Mechanism of Alzheimer's Disease and Its Potential for Therapeutic Intervention.

Authors:  Tiantian Li; Li Lu; Eloise Pember; Xinuo Li; Bocheng Zhang; Zheying Zhu
Journal:  Cells       Date:  2022-06-14       Impact factor: 7.666

Review 2.  ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease.

Authors:  Yonghe Li; Jesse R Macyczko; Chia-Chen Liu; Guojun Bu
Journal:  Neurobiol Aging       Date:  2022-03-22       Impact factor: 5.133

Review 3.  Connecting the Dots Between Hypercholesterolemia and Alzheimer's Disease: A Potential Mechanism Based on 27-Hydroxycholesterol.

Authors:  Mingan Wu; Yingying Zhai; Xiaoyi Liang; Weichun Chen; Ruiyi Lin; Linlin Ma; Yi Huang; Di Zhao; Yong Liang; Wei Zhao; Jiansong Fang; Shuhuan Fang; Yunbo Chen; Qi Wang; Weirong Li
Journal:  Front Neurosci       Date:  2022-04-07       Impact factor: 5.152

Review 4.  Alzheimer's Disease: Current Perspectives and Advances in Physiological Modeling.

Authors:  E Josephine Boder; Ipsita A Banerjee
Journal:  Bioengineering (Basel)       Date:  2021-12-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.